Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2
Journal
The oncologist
Journal Volume
27
Journal Issue
12
Date Issued
2022-12-09
Author(s)
Finn, Richard S
Yau, Thomas
De Toni, Enrico N
Goyal, Lipika
Galle, Peter R
Qin, ShuKui
Rao, Sujata
Sun, Fangfang
Wang, Chunxiao
Widau, Ryan C
Zhu, Andrew X
Abstract
Ramucirumab is indicated for patients with advanced hepatocellular carcinoma (HCC) and α-fetoprotein (AFP) ≥400 ng/mL following sorafenib. Here, we prospectively studied ramucirumab following non-sorafenib systemic therapies.
Subjects
advanced hepatocellular carcinoma (HCC); non-sorafenib; ramucirumab; α-fetoprotein
Publisher
OXFORD UNIV PRESS
Type
journal article